Testing effectiveness (Phase 2)UnknownNCT03737968
What this trial is testing
Window of Opportunity Trial of Durvalumab (MEDI4736) or Durvalumab/Tremelimumab as Neoadjuvant Chemotherapy to Identify Immune Dynamics in Surgically Resectable Head and Neck Cancer Patients.
Who this might be right for
Stage II-IVB Operable HNSCC Oral CavityHypopharynxOropharynx+1 more
Yonsei University 48